These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31289949)

  • 1. Low percentages of measles vaccination coverage with two doses of vaccine and low herd immunity levels explain measles incidence and persistence of measles in the European Union in 2017-2018.
    Plans-Rubió P
    Eur J Clin Microbiol Infect Dis; 2019 Sep; 38(9):1719-1729. PubMed ID: 31289949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why does measles persist in Europe?
    Plans-Rubió P
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1899-1906. PubMed ID: 28550369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mandatory Vaccination in Europe.
    Vaz OM; Ellingson MK; Weiss P; Jenness SM; Bardají A; Bednarczyk RA; Omer SB
    Pediatrics; 2020 Feb; 145(2):. PubMed ID: 31932361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of herd immunity against measles in individuals aged <35 years could explain re-emergence of measles in Catalonia (Spain).
    Plans P; Torner N; Godoy P; Jané M
    Int J Infect Dis; 2014 Jan; 18():81-3. PubMed ID: 24211476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination Coverage for Routine Vaccines and Herd Immunity Levels against Measles and Pertussis in the World in 2019.
    Plans-Rubió P
    Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33805681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating age-specific vaccine effectiveness using data from a large measles outbreak in Berlin, Germany, 2014/15: evidence for waning immunity.
    Bitzegeio J; Majowicz S; Matysiak-Klose D; Sagebiel D; Werber D
    Euro Surveill; 2019 Apr; 24(17):. PubMed ID: 31039834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress Toward Measles Elimination - European Region, 2009-2018.
    Zimmerman LA; Muscat M; Singh S; Ben Mamou M; Jankovic D; Datta S; Alexander JP; Goodson JL; O'Connor P
    MMWR Morb Mortal Wkly Rep; 2019 May; 68(17):396-401. PubMed ID: 31048675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herd immunity and primary immune deficiencies.
    Farrugia A; Quinti I
    Vaccine; 2019 Jul; 37(30):3942-3943. PubMed ID: 30497836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of herd immunity in control of measles.
    Black FL
    Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A measles epidemic threshold in a highly vaccinated population.
    Wallinga J; Heijne JC; Kretzschmar M
    PLoS Med; 2005 Nov; 2(11):e316. PubMed ID: 16218769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination.
    Funk S; Knapp JK; Lebo E; Reef SE; Dabbagh AJ; Kretsinger K; Jit M; Edmunds WJ; Strebel PM
    BMC Med; 2019 Sep; 17(1):180. PubMed ID: 31551070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles Resurgence in Europe: Migrants and Travellers are not the Main Drivers.
    Leong WY; Wilder-Smith AB
    J Epidemiol Glob Health; 2019 Dec; 9(4):294-299. PubMed ID: 31854172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing age-dependent susceptibility to measles in Japan.
    Kinoshita R; Nishiura H
    Vaccine; 2017 Jun; 35(25):3309-3317. PubMed ID: 28501456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy.
    Garly ML; Martins CL; Balé C; da Costa F; Dias F; Whittle H; Aaby P
    Int J Epidemiol; 1999 Apr; 28(2):347-52. PubMed ID: 10342702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles vaccination in an increasingly immunized and developed world.
    Hayman DTS
    Hum Vaccin Immunother; 2019; 15(1):28-33. PubMed ID: 30156949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles vaccination coverage in high-incidence areas of the Western Cape, following the mass vaccination campaign.
    Bernhardt GL; Cameron NA; Willems B; Boulle A; Coetzee D
    S Afr Med J; 2013 Jan; 103(3):181-6. PubMed ID: 23472696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage.
    Plans-Rubió P
    Hum Vaccin Immunother; 2012 Feb; 8(2):184-8. PubMed ID: 22426372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of low measles vaccination coverage in children living in an endemic area.
    Lo Vecchio A; Cambriglia MD; Fedele MC; Basile FW; Chiatto F; Miraglia Del Giudice M; Guarino A
    Eur J Pediatr; 2019 Feb; 178(2):243-251. PubMed ID: 30430239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transport networks and inequities in vaccination: remoteness shapes measles vaccine coverage and prospects for elimination across Africa.
    Metcalf CJ; Tatem A; Bjornstad ON; Lessler J; O'Reilly K; Takahashi S; Cutts F; Grenfell BT
    Epidemiol Infect; 2015 May; 143(7):1457-66. PubMed ID: 25119237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study.
    Bolotin S; Severini A; Hatchette T; McLachlan E; Savage R; Hughes SL; Wang J; Deeks SL; Wilson S; Brisson M; Halperin SA; Gubbay J; Mazzulli T; Serhir B; Ward BJ; Crowcroft N
    Hum Vaccin Immunother; 2019; 15(12):2856-2864. PubMed ID: 31184979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.